From tradition to regulation: Clinical trials as enablers of safe and evidence-based herbal product approval
International Journal of Ayurveda Research · 2026-10 · 7 (4) · 418-429
DOI: 10.4103/ijar.ijar_104_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Ayurveda Research, online erschienen am 20.11.2026. Verfasst von Abhijit Dutta und 3 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Herbal products are rapidly expanding globally, yet regulatory pathways remain heterogeneous and scientifically contested. A critical gap exists in understanding how clinical trials function as regulatory enablers across diverse jurisdictional contexts, and what methodological and policy challenges impede their wider adoption. To address this, a narrative structured review with a policy-informing scope was conducted using literature retrieved from PubMed, Scopus, and Web of Science covering the period from January 2000 to April 2026. Official regulatory documents from the World Health Organization, United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), Central Drugs Standard Control Organization (CDSCO), Ministry of Ayush (MoA), Eurasian Economic Union (EAEU), Association of Southeast Asian Nations (ASEAN), and European Food Safety Authority (EFSA) were also included. Of 735 records identified, 69 peer-reviewed publications and regulatory guidelines were included. Regulatory frameworks varied across countries, reflecting distinct cultural, economic, and political priorities. Across jurisdictions, greater clinical evidence was generally associated with broader regulatory acceptance. Case studies of plant sterols, Ashwagandha ( Withania somnifera [L.] Dunal), red yeast rice, and Ginkgo biloba L. illustrated how clinical evidence, standardization, and trial outcomes influence regulatory decisions. Overall, the evidence indicates that clinical trials are the key determinant distinguishing authorized herbal nutraceuticals from those that are restricted or rejected. Future priorities should focus on regulatory harmonization, adaptive clinical trial designs, phytochemical standardization, and the integration of real-world evidence to fully realize the potential of herbal products within evidence-based integrative healthcare.
Zitieren
APA
Dutta, A., Raghu, A., Kumar, S., & Kaushik, R. (2026). From tradition to regulation: Clinical trials as enablers of safe and evidence-based herbal product approval. International Journal of Ayurveda Research, 7(4), 418-429. https://doi.org/10.4103/ijar.ijar_104_26
Vancouver
Dutta A, Raghu A, Kumar S, Kaushik R. From tradition to regulation: Clinical trials as enablers of safe and evidence-based herbal product approval. International Journal of Ayurveda Research. 2026;7(4):418-429. doi:10.4103/ijar.ijar_104_26
BibTeX
@article{Dutta2026,
author = {Dutta, Abhijit and Raghu, Arackal and Kumar, Shobhit and Kaushik, Raman},
title = {From tradition to regulation: Clinical trials as enablers of safe and evidence-based herbal product approval},
journal = {International Journal of Ayurveda Research},
year = {2026},
volume = {7},
number = {4},
pages = {418--429},
doi = {10.4103/ijar.ijar_104_26}
}
EUVIMED